Biopharmaceutics classification system (BCS)-based biowaiver for immediate release solid oral dosage forms of moxifloxacin hydrochloride (Moxiflox GPO) manufactured by the Government Pharmaceutical Organization (GPO)
Saved in:
Main Authors: | Nawaphon Saelim (Author), Khemjira Suksawaeng (Author), Jutamat Chupan (Author), Isariya Techatanawat (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2016-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biopharmaceutics classification system: importance and inclusion in biowaiver guidance
by: Lorena Barbosa Arrunátegui, et al.
Published: (2015) -
Pediatric Biopharmaceutical Classification Systems (pBCS)
by: Justyna Srebro, et al.
Published: (2023) -
Effects of experimental conditions on solubility measurements for BCS classification in order to improve the biowaiver guidelines
by: Patrícia Fernanda Monteiro, et al.
Published: (2021) -
A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme
by: Joy Elizabeth van Oudtshoorn, et al.
Published: (2018) -
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development
by: Wolk O, et al.
Published: (2014)